NCT03287414 - Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2017

Primary Completion Date

November 25, 2020

Study Completion Date

February 14, 2022

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

VAY736

300 mg VAY736 administered subcutaneously every 4 weeks for 48 weeks

DRUG

Placebo

Placebo administered subcutaneously every 4 weeks for 48 weeks

DRUG

Standard of Care (SoC)

Background standard-of-care treatment for IPF: nintedanib, pirfenidone, or no background therapy

Trial Locations (16)

15213

Novartis Investigative Site, Pittsburgh

27710

Novartis Investigative Site, Durham

30625

Novartis Investigative Site, Hanover

33136

Novartis Investigative Site, Miami

37203

Novartis Investigative Site, Nashville

41124

Novartis Investigative Site, Modena

47100

Novartis Investigative Site, Forlì

53100

Novartis Investigative Site, Siena

80045

Novartis Investigative Site, Aurora

84108

Novartis Investigative Site, Salt Lake City

35294-0007

Novartis Investigative Site, Birmingham

T2N 2T9

Novartis Investigative Site, Calgary

01640

Novartis Investigative Site, Coswig

D04

Novartis Investigative Site, Dublin

CB23 3RE

Novartis Investigative Site, Cambridge

NE7 7DN

Novartis Investigative Site, High Heaton